Future improvements in assay standardization, mechanistic investigations, and controlled therapeutic trials—especially those focusing on anti-IgE treatments—will determine the role of IgE-targeted approaches in standard protocols for autoimmune diseases (19, 311). This evidence concerns the gene IGHE and autoimmune disease.